Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 versus best supportive care in ASS1-negative malignant pleural mesothelioma
ISRCTN71601938Phase 2Completed
- Sponsor
- Barts Health NHS Trust
- Start
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial in pleural mesothelioma comparing Best supportive care with ADI-PEG 20 plus best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Mar 2011; status: completed.
02
Drugs
Pegargiminase
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on ISRCTN71601938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71601938.